Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 5, 2013, Pages 411-415

  Akiyoshi, Takeshi ^a   Ito, Marie ^a   Murase, Saori ^a   Miyazaki, Mitsue ^b   Peter Guengerich, F ^c   Nakamura, Katsunori ^d   Yamamoto, Koujirou ^b   Ohtani, Hisakazu ^a  

^a KEIO UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Clarithromycin; CYP3A4; Erythromycin; Genetic variants; Mechanism based inhibition

Indexed keywords

6BETA HYDROXYTESTOSTERONE; CLARITHROMYCIN; CYTOCHROME P450 3A4; ERYTHROMYCIN; RECOMBINANT CYTOCHROME P450 3A4; RECOMBINANT ENZYME; TESTOSTERONE; TESTOSTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYP3A4 GENE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME KINETICS; GENETIC VARIABILITY; HYDROXYLATION; QUANTITATIVE STUDY;

CLARITHROMYCIN; CYTOCHROME P-450 CYP3A; ERYTHROMYCIN; STEROID HYDROXYLASES;

EID: 84886403500     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-134     Document Type: Article

References (31)

1. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F. P.: Interindividual variation in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals. J. Pharmacol. Exp. Ther., 270: 414-423 (1994).
2. Guengerich, F. P.: Human cytochrome P450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol., 39: 1-17 (1999).
3. Guengerich, F. P.: Cytochrome P450 and chemical toxicology. Chem. Res. Toxicol., 21: 70-83 (2008).
4. http://www.cypalleles.ki.se/cyp3a4.htm the Human Cytochrome P450 (CYP) Allele Nomenclature Committee Web Site.
5. Miyazaki, M., Nakamura, K., Fujita, Y., Guengerich, F. P., Horiuchi, R. and Yamamoto, K.: Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone. Drug Metab. Dispos., 36: 2287-2291 (2008).
6. Akiyoshi, T., Saito, T., Murase, S., Miyazaki, M., Murayama, N., Yamazaki, H., Guengerich, F. P., Nakamura, K., Yamamoto, K. and Ohtani, H.: Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants. Drug Metab. Dispos., 39: 724-728 (2011).
7. Sekiguchi, N., Higashida, A., Kato, M., Nabuchi, Y., Mitsui, T., Takanashi, K., Aso, Y. and Ishigai, M.: Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. Drug Metab. Pharmacokinet., 24: 500-510 (2009).
8. Polasek, T. M. and Miners, J. O.: Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur. J. Clin. Pharmacol., 62: 203-208 (2006).
9. Jones, D. R., Ekins, S., Li, L. and Hall, S. D.: Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5). Drug Metab. Dispos., 35: 1466-1475 (2007).
10. Ernest, C. S., 2nd, Hall, S. D. and Jones, D. R.: Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J. Pharmacol. Exp. Ther., 312: 583-591 (2005).
11. Lim, K. S., Cho, J. Y., Jang, I. J., Kim, B. H., Kim, J., Jeon, J. Y., Tae, Y. M., Yi, S., Eum, S., Shin, S. G. and Yu, K. S.: Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects. Br. J. Clin. Pharmacol., 66: 660-666 (2008).
12. Yamaoka, K., Tanigawara, Y., Nakagawa, T. and Uno, T.: A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn., 4: 879-885 (1981).
13. Sata, F., Sapone, A., Elizondo, G., Stocker, P., Miller, V. P., Zheng, W., Raunio, H., Crespi, C. L. and Gonzalez, F. J.: CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther., 67: 48-56 (2000).
14. Eiselt, R., Domanski, T. L., Zibat, A., Mueller, R., Presecan-Siedel, E., Hustert, E., Zanger, U. M., Brockmoller, J., Klenk, H. P., Meyer, U. A., Khan, K. K., He, Y. A., Halpert, J. R. and Wojnowski, L.: Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics, 11: 447-458 (2001).
15. Lamba, J. K., Lin, Y. S., Thummel, K., Daly, A., Watkins, P. B., Strom, S., Zhang, J. and Schuetz, E. G.: Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics, 12: 121-132 (2002).
16. Fukushima-Uesaka, H., Saito, Y., Watanabe, H., Shiseki, K., Saeki, M., Nakamura, T., Kurose, K., Sai, K., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Hanai, S., Nakajima, T., Matsumoto, K., Saito, H., Goto, Y., Kimura, H., Katoh, M., Sugai, K., Minami, N., Shirao, K., Tamura, T., Yamamoto, N., Minami, H., Ohtsu, A., Yoshida, T., Saijo, N., Kitamura, Y., Kamatani, N., Ozawa, S. and Sawada, J.: Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum. Mutat., 23: 100 (2004).
17. Murayama, N., Nakamura, T., Saeki, M., Soyama, A., Saito, Y., Sai, K., Ishida, S., Nakajima, O., Itoda, M., Ohno, Y., Ozawa, S. and Sawada, J.: CYP3A4 Gene polymorphisms influence testosterone 6¢-hydroxylation. Drug Metab. Pharmacokinet., 17: 150-156 (2002).
18. Austin, R. P., Barton, P., Cockroft, S. L., Wenlock, M. C. and Riley, R. J.: The influence of nonspecific microsmal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab. Dispos., 30: 1497-1503 (2002).
19. Austin, R. P., Barton, P., Mohmed, S. and Riley, R. J.: The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab. Dispos., 33: 419-425 (2005).
20. Gotoh, O.: Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J. Biol. Chem., 267: 83-90 (1992).
21. Johnson, E. F. and Waterman, M. R.: Structural alignments of P450s and extrapolations to the unknown. In Graham-Lorence, S. E. and Peterson, J. A. (eds.): Methods in Enzymology, New York, Academic Press, 1996, pp. 315-327.
22. Williams, P. A., Cosme, J., Sridhar, V., Johnson, E. F. and McRee, D. E.: Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell, 5: 121-131 (2000).
23. Khan, K. K., He, Y. Q., Domanski, T. L. and Halpert, J. R.: Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol. Pharmacol., 61: 495-506 (2002).
24. Wang, H., Dick, R., Yin, H., Licad-Coles, E., Kroetz, D. L., Szklarz, G., Harlow, G., Halpert, J. R. and Correia, M. A.: Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe. Biochemistry, 37: 12536-12545 (1998).
25. Yano, J. K., Wester, M. R., Schoch, G. A., Griffin, K. J., Stout, C. D. and Johnson, E. F.: The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-Å resolution. J. Biol. Chem., 279: 38091-38094 (2004).
26. Davydov, D. R., Rumfeldt, J. A., Sineva, E. V., Fernando, H., Davydova, N. Y. and Halpert, J. R.: Peripheral ligand-binding site in cytochrome P450 3A4 located with fluorescence resonance energy transfer (FRET). J. Biol. Chem., 287: 6797-6809 (2012).
27. Zhou, Z. W. and Zhou, S. F.: Application of mechanism-based CYP inhibition for predicting drug-drug interactions. Expert Opin. Drug Metab. Toxicol., 5: 579-605. Review (2009).
28. Kumar, V., Wahlstrom, J. L., Rock, D. A., Warren, C. J., Gorman, L. A. and Tracy, T. S.: CYP2C9 inhibition: Impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab. Dispos., 34: 1966-1975 (2006).
29. Jamei, M., Dickinson, G. L. and Rostami-Hodjegan, A.: A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab. Pharmacokinet., 24: 53-75 (2009).
30. Fowler, S. M., Taylor, J. M., Friedberg, T., Wolf, C. R. and Riley, R. J.: CYP3A4 active site volume modification by mutagenesis of leucine 211. Drug Metab. Dispos., 30: 452-456 (2002).
31. Taesotikul, T., Dumrongsakulchai, W., Wattanachai, N., Navinpipat, V., Somanabandhu, A., Tassaneeyakul, W. and Tassaneeyakul, W.: Inhibitory effects of Phyllanthus amarus and its major lignans on human microsomal cytochrome P450 activities: evidence for CYP3A4 mechanism-based inhibition. Drug Metab. Pharmacokinet., 26: 154-161 (2011).